Related Experiment Video

Updated: Sep 10, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K

Benefits of a comprehensive care model in patients with heart failure and atrial fibrillation: UMIPIC Program

José Luis García-Klepzig1, Manuel Méndez Bailón2, Manuel Montero-Pérez-Barquero3

  • 1Servicio de Medicina Interna, Hospital Clínico San Carlos, Facultad de Enfermería, Fisioterapia y Podología, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IDISSC), Madrid, España.

Medicina Clinica
|August 27, 2025
PubMed

Insights

The UMIPIC program, offering comprehensive care for heart failure and atrial fibrillation patients, significantly reduced hospital admissions and mortality within one year. This innovative approach improved patient outcomes without increasing stroke risk.

Area of Science:

  • Cardiology
  • Public Health
  • Healthcare Management

Background:

  • Patients with heart failure (HF) and atrial fibrillation (AF) face elevated risks of hospital admission and mortality.
  • A comprehensive and continuous care model, the UMIPIC program, was implemented to address these risks.

Purpose of the Study:

  • To evaluate the effectiveness of the UMIPIC program in managing patients with both HF and AF.
  • To assess the impact of this care model on hospital admissions, mortality, and stroke incidence.

Main Methods:

  • A prospective study involving 5644 patients, with 3005 having a history of AF, recruited between March 2008 and March 2020.
  • Patients were divided into the UMIPIC program group (1142) or conventional care group (1863) post-discharge.
  • Propensity score matching was used to create comparable cohorts for analysis of 12-month outcomes.

Main Results:

  • The UMIPIC group showed significantly lower all-cause admissions (35.6% vs. 44.8%) and HF admissions (18.3% vs. 29.6%) compared to the conventional group.
  • Overall mortality was reduced in the UMIPIC group (23.2% vs. 31%).
  • No significant difference in the incidence of ischemic stroke was observed between the groups.

Conclusions:

  • The UMIPIC care program effectively reduces hospital admissions and mortality in patients with HF and AF.
  • Comprehensive and continuous care models can improve outcomes for high-risk patient populations.
  • The UMIPIC program demonstrates a favorable risk-benefit profile, with no increase in ischemic stroke rates.
Abstract

Keywords:
Atrial fibrillationFibrilación auricularHeart failureInsuficiencia cardiacaMortalidadMortalityProgramaProgrammeReadmissionsReingresosUMIPIC

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.6K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

872

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
26
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21